Global Liver Institute and TriSalus Life Sciences Partner To Launch “Liver Central,” a New Resource Hub for Liver Cancer Researchers, Clinicians and Patients
January 06, 2022 10:04 ET | Global Liver Institute
Sterling, Jan. 06, 2022 (GLOBE NEWSWIRE) -- The Global Liver Institute (GLI), the only patient-led liver health nonprofit operating internationally, in partnership with TriSalus Life Sciences®, an...
Global Liver Institute Recognized with Two Advocacy Awards for Enduring Contributions and Sustained Service
November 19, 2021 11:58 ET | Global Liver Institute
Washington, DC, USA, Nov. 19, 2021 (GLOBE NEWSWIRE) -- (Washington, DC, Friday, November 19, 2021) — Global Liver Institute (GLI), the only patient-led liver health nonprofit operating...
The New England Journal of Medicine publishes the results of the NATIVE Phase IIb clinical trial with lanifibranor in NASH
October 20, 2021 17:07 ET | INVENTIVA
In the Phase IIb NATIVE, lanifibranor met both the primary and key secondary endpoints, including NASH resolution with no worsening of fibrosis and improvement of liver fibrosis with no worsening of...
« The New England Journal of Medicine » publie les résultats de l’étude clinique de Phase IIb NATIVE d’Inventiva avec lanifibranor dans la NASH
October 20, 2021 17:07 ET | INVENTIVA
Dans l’étude clinique de Phase IIb, lanifibranor avait atteint les critères d’évaluation principaux et secondaires, incluant la résolution de la NASH sans aggravation de la fibrose et l'amélioration...
Inventiva announces the presentation of five scientific abstracts at the AASLD The Liver Meeting™ 2021
October 18, 2021 16:00 ET | INVENTIVA
Four poster presentations add to the evidence of the beneficial effects of lanifibranor therapy on key components of NASH, following further sub-analyses of Inventiva’s NATIVE Phase IIb clinical trial...
Inventiva annonce la présentation de cinq abstracts scientifiques lors du The Liver Meeting™ 2021 organisé par l’AASLD
October 18, 2021 16:00 ET | INVENTIVA
Quatre présentations par poster confirment les effets bénéfiques de lanifibranor sur des composants clés de la NASH faisant suite à des analyses supplémentaires réalisées sur les résultats de l'étude...
researchdrivelogo.jpg
Global Organ Care System for Liver Market Predicted to Garner a Revenue of $42.7 Million at a CAGR of 9.3% during the Forecast Period, 2019-2026 COVID-19 Disaster - Exclusive Report by Research Dive
September 21, 2021 09:35 ET | Research Dive
New York, USA, Sept. 21, 2021 (GLOBE NEWSWIRE) -- According to a recent report by Research Dive, the global organ care system for liver market is forecasted to reach $42.7 million by the end of...
Inventiva’s 2021 First-Half Financial Results Presentation
September 10, 2021 09:00 ET | INVENTIVA
Daix (France), September 10, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment...
Présentation des résultats financiers du 1er semestre 2021 d’Inventiva
September 10, 2021 09:00 ET | INVENTIVA
Daix (France), le 10 septembre 2021 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de petites molécules administrées par voie orale...
researchdrivelogo.jpg
Global Cancer Stem Cells Market to Surpass $1,898.3 Million, Growing with a CAGR of 11.8% from 2019 to 2026, Post-COVID-19 Disaster by Research Dive
August 17, 2021 09:02 ET | Research Dive
New York, USA, Aug. 17, 2021 (GLOBE NEWSWIRE) -- A newest report on the global cancer stem cells market has been added by Research Dive to its repository. The report presents exhaustive insights on...